Leon De Windt

Prof. Leon De Windt

orcid

Research Focus & Metrics

Academic Career Length

18Years (2009-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
19 January 2012 in Cardiovascular Research
Verified
Journal Article
Open access
PDF file
PMPaula A. Da Costa Martins
Paula A. Da Costa Martins
LWLeon De Windt
Leon De Windt
MicroRNAs refer to a subfamily of small non-coding RNA species that are designed to influence gene expression in nearly all cell types studied to date. Studies from the past decade have demonstrated that microRNAs are atypically expressed in the cardiovascular system under specific pathological conditions. Gain- and loss-of-function studies using in vitro and in vivo models have revealed distinct roles for specific microRNAs in cardiovascular development, physiological functions, and cardiac pathological conditions. In this review, the current relevant findings on the role of microRNAs in cardiac hypertrophic growth are updated, the target genes of these microRNAs are summarized, and the future of microRNAs as potential therapeutic targets is discussed.

Verified
Journal Article
Open access
PDF file
CSClaudia Sacchetto
Claudia Sacchetto
LVLIBERO VITIELLO
LIBERO VITIELLO
LWLeon De Windt
Leon De Windt
Alessandra RampazzoAlessandra Rampazzo
Alessandra Rampazzo
Martina CaloreMartina Calore
Martina Calore
In the last decade, the generation of cardiac disease models based on human-induced pluripotent stem cells (hiPSCs) has become of common use, providing new opportunities to overcome the lack of appropriate cardiac models. Although much progress has been made toward the generation of hiPSC-derived cardiomyocytes (hiPS-CMs), several lines of evidence indicate that two-dimensional (2D) cell culturing presents significant limitations, including hiPS-CMs immaturity and the absence of interaction between different cell types and the extracellular matrix. More recently, new advances in bioengineering and co-culture systems have allowed the generation of three-dimensional (3D) constructs based on hiPSC-derived cells. Within these systems, biochemical and physical stimuli influence the maturation of hiPS-CMs, which can show structural and functional properties more similar to those present in adult cardiomyocytes. In this review, we describe the latest advances in 2D- and 3D-hiPSC technology for cardiac disease mechanisms investigation, drug development, and therapeutic studies.

1 September 2015 in Trends in Endocrinology & Metabolism
Verified
Journal Article
Closed access
HAHamid el Azzouzi
Hamid el Azzouzi
SLStefanos Leptidis
Stefanos Leptidis
PDPieter A. Doevendans
Pieter A. Doevendans
LWLeon De Windt
Leon De Windt

1 March 2019 in Molecular Therapy
Verified
Journal Article
Open access
ARAndrea Raso
Andrea Raso
EDEllen Dirkx
Ellen Dirkx
LPLeonne E. Philippen
Leonne E. Philippen
AFAmaya Fernandez-Celis
Amaya Fernandez-Celis
FMFederica De Majo
Federica De Majo
LWLeon De Windt
Leon De Windt
Heart failure is preceded by ventricular remodeling, changes in left ventricular mass, and myocardial volume after alterations in loading conditions. Concentric hypertrophy arises after pressure overload, involves wall thickening, and forms a substrate for diastolic dysfunction. Eccentric hypertrophy develops in volume overload conditions and leads wall thinning, chamber dilation, and reduced ejection fraction. The molecular events underlying these distinct forms of cardiac remodeling are poorly understood. Here, we demonstrate that miR-148a expression changes dynamically in distinct subtypes of heart failure: while it is elevated in concentric hypertrophy, it decreased in dilated cardiomyopathy. In line, antagomir-mediated silencing of miR-148a caused wall thinning, chamber dilation, increased left ventricle volume, and reduced ejection fraction. Additionally, adeno-associated viral delivery of miR-148a protected the mouse heart from pressure-overload-induced systolic dysfunction by preventing the transition of concentric hypertrophic remodeling toward dilation. Mechanistically, miR-148a targets the cytokine co-receptor glycoprotein 130 (gp130) and connects cardiomyocyte responsiveness to extracellular cytokines by modulating the Stat3 signaling. These findings show the ability of miR-148a to prevent the transition of pressure-overload induced concentric hypertrophic remodeling toward eccentric hypertrophy and dilated cardiomyopathy and provide evidence for the existence of separate molecular programs inducing distinct forms of myocardial remodeling.

1 December 2015 in Journal of Molecular and Cellular Cardiology
Verified
Journal Article
Closed access
LPLeonne E. Philippen
Leonne E. Philippen
EDEllen Dirkx
Ellen Dirkx
PCPaula A. da Costa-Martins
Paula A. da Costa-Martins
LWLeon De Windt
Leon De Windt

1 January 2013 in Frontiers in Genetics
Verified
Journal Article
Open access
PDF file
VKVirginie Kinet
Virginie Kinet
JHJulie Halkein
Julie Halkein
EDEllen Dirkx
Ellen Dirkx
LWLeon De Windt
Leon De Windt
Cardiovascular diseases are a leading cause of morbidity and mortality in Western societies. It is now well established that microRNAs (miRNAs) are determinant regulators in various medical conditions including cardiovascular diseases. The recent discovery that miRNAs, while associated with different carriers, can be exported out of the cell, has triggered a renewed interest to analyze the potential to use extracellular microRNAs as tools for diagnostic and therapeutic studies. Circulating miRNAs in biological fluids present a technological advantage compared to current diagnostic tools by virtue of their remarkable stability and relative ease of detection rendering them ideal tools for noninvasive and rapid diagnosis. Extracellular miRNAs also represent a novel form of inter-cellular communication by transfering genetic information from a donor cell to a recipient cell. This review briefly summarizes recent insights in the origin, function and diagnostic potential of extracellular miRNAs by focusing on a select number of cardiovascular diseases.